Table 2 Salvage treatment and outcome of all refractory/relapsed patients
# of patient | Second line of chemotherapy | HSCT | Response | Outcome |
|---|---|---|---|---|
Refractory patients | ||||
1 | ICE | Yes | RD | Died from disease |
2 | ESHAP/brentuximab vedotin | Yes | CR2 | Alive in CR |
3 | ICE | Yes | CR2 | Alive in CR |
4 | ESHAP/brentuximab vedotin | Yes | CR2 | Alive in CR |
5 | ICE | No | RD | Died from disease |
6 | ICE then ESHAP/brentuximab vedotin | No | RD | Alive with disease |
7 | ICE | Yes | CR2 | Alive in CR |
8 | ICE then ESHAP/brentuximab vedotin | Yes | CR2 | Alive in CR |
Relapsed patients | ||||
1 | ICE then gemcitabine/brentuximab vedotin | No | RD | Died from disease |
2 | ICE | No | CR2 | Alive in CR |
3 | ICE | No | CR2 | Alive in CR |
4 | ICE | No | CR2 | Alive in CR |
5 | ICE | Yes | CR2 | Alive in CR |
6 | ICE | Yes | CR2 | Alive in CR |
7 | ESHAP/brentuximab vedotin | Yes | CR2 | Alive in CR |
8 | ICE | Yes | CR2 | Alive in CR |
9 | Refused treatment | No | RD | Alive with disease |
10 | ICE then gemcitabine/brentuximab vedotin | Yes | CR2 | Alive in CR |
11 | ESHAP/brentuximab vedotin | Yes | CR2 | Alive with 2ry neoplasm |